Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 05, 2026 07:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces First Quarter 2026 Results and Business Updates

EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, on track to achieve early human proof-of-concept data by year-end 2026 Company to present new EDIT-401 preclinical...